{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T21:47:49Z","timestamp":1696628869628},"reference-count":159,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,1,14]],"date-time":"2015-01-14T00:00:00Z","timestamp":1421193600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychiatr"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s40211-014-0132-8","type":"journal-article","created":{"date-parts":[[2015,1,13]],"date-time":"2015-01-13T10:18:21Z","timestamp":1421144301000},"page":"1-13","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Parkinson-Krankheit und Psychosen"],"prefix":"10.1007","volume":"29","author":[{"given":"Jacopo Vittoriano","family":"Bizzarri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Giupponi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignazio","family":"Maniscalco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Schroffenegger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Conca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Peter","family":"Kapfhammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,1,14]]},"reference":[{"key":"132_CR1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/mds.10010","volume":"17","author":"Global Parkinson\u2019s Disease Survey Steering Committee","year":"2002","unstructured":"Global Parkinson\u2019s Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson\u2019s disease: results from an international survey. Mov Disord. 2002;17:60\u20137.","journal-title":"Mov Disord"},{"key":"132_CR2","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1212\/WNL.43.11.2227","volume":"43","author":"CG Goetz","year":"1993","unstructured":"Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson\u2019s disease. Neurology. 1993;43:2227\u20139.","journal-title":"Neurology"},{"key":"132_CR3","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1212\/WNL.45.4.669","volume":"45","author":"CG Goetz","year":"1995","unstructured":"Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson\u2019s disease. Neurology. 1995;45:669\u201371.","journal-title":"Neurology"},{"key":"132_CR4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/mds.870130108","volume":"13","author":"JH Carter","year":"1998","unstructured":"Carter JH, Stewart BJ, Archbold PG, et al. Living with a person who has Parkinson\u2019s disease: the spouse\u2019s perspective by stage of disease. Mov Disord. 1998;13:20\u20138.","journal-title":"Mov Disord"},{"key":"132_CR5","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/(SICI)1099-1166(199910)14:10<866::AID-GPS38>3.0.CO;2-Z","volume":"14","author":"D Aarsland","year":"1999","unstructured":"Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinson\u2019s disease are important contributors to caregiver distress. Int J Geriatr Psychiatry. 1999;14:866\u201374.","journal-title":"Int J Geriatr Psychiatry"},{"key":"132_CR6","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1532-5415.2000.tb06891.x","volume":"48","author":"D Aarsland","year":"2000","unstructured":"Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson\u2019s disease: a population-based, prospective study. J Am Geriatr Soc. 2000;48:938\u201342.","journal-title":"J Am Geriatr Soc"},{"key":"132_CR7","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1212\/01.WNL.0000068010.82167.CF","volume":"60","author":"SA Factor","year":"2003","unstructured":"Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, Kurlan R, Parsa M, Pfeiffer R. Parkinson Study Group. Longitudinal outcome of Parkinson\u2019s disease patients with psychosis. Neurology. 2003;60:1756\u201361.","journal-title":"Neurology"},{"issue":"1","key":"132_CR8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.2005.083113","volume":"78","author":"D Aarsland","year":"2007","unstructured":"Aarsland D, Bronnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson\u2019s disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry. 2007;78(1):36\u201342.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"132_CR9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.parkreldis.2007.05.009","volume":"14","author":"A McKinlay","year":"2008","unstructured":"McKinlay A, Grace RC, Dalrymple-Alford JC, et al. A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson\u2019s disease patients without dementia. Parkinsonism Relat Disord. 2008;14:37\u201342.","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"132_CR10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archneur.56.5.595","volume":"56","author":"D Aarsland","year":"1999","unstructured":"Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol. 1999;56(5):595\u2013601.","journal-title":"Arch Neurol"},{"key":"132_CR11","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.psc.2004.07.001","volume":"27","author":"EC Lauterbach","year":"2004","unstructured":"Lauterbach EC. The neuropsychiatry of Parkinson\u2019s disease and related disorders. Psychiatr Clin North Am. 2004;27:801\u201325.","journal-title":"Psychiatr Clin North Am"},{"issue":"2","key":"132_CR12","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000129843.15756.A3","volume":"63","author":"L Marsh","year":"2004","unstructured":"Marsh L, Williams JR, Rocco M, Grill S, Munro C, Dawson TM. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology. 2004;63(2):293\u2013300.","journal-title":"Neurology"},{"key":"132_CR13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.parkreldis.2006.03.006","volume":"12","author":"D Weintraub","year":"2006","unstructured":"Weintraub D, Morales KH, Duda JE, Moberg PJ, Stern MB. Frequency and correlates of co-morbid psychosis and depression in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2006;12:427\u201331.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1\u20132","key":"132_CR14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jns.2009.08.014","volume":"289","author":"G F\u00e9nelon","year":"2010","unstructured":"F\u00e9nelon G, Alves G. Epidemiology of psychosis in Parkinson\u2019s disease. J Neurol Sci. 2010;289(1\u20132):12\u20137.","journal-title":"J Neurol Sci"},{"issue":"1","key":"132_CR15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1176\/jnp.2010.22.1.105","volume":"22","author":"RJ Holt","year":"2010","unstructured":"Holt RJ, Sklar AR, Darkow T, Goldberg GA, Johnson JC, Harley CR. Prevalence of Parkinson\u2019s disease-induced psychosis in a large U.S. managed care population. J Neuropsychiatry Clin Neurosci. 2010;22(1):105\u201310.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"2","key":"132_CR16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/JGP.0b013e31821f1b41","volume":"20","author":"J Mack","year":"2012","unstructured":"Mack J, Rabins P, Anderson K, Goldstein S, Grill S, Hirsch ES, Lehmann S, Little JT, Margolis RL, Palanci J, Pontone G, Weiss H, Williams JR, Marsh L. Prevalence of psychotic symptoms in a community-based Parkinson disease sample. Am J Geriatr Psychiatry. 2012;20(2):123\u201332.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"8","key":"132_CR17","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/mds.21382","volume":"22","author":"B Ravina","year":"2007","unstructured":"Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson\u2019s disease: report of an NINDS\/NIMH work group. Mov Disord. 2007;22(8):1061\u20138.","journal-title":"Mov Disord"},{"key":"132_CR18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11940-004-0010-y","volume":"6","author":"L Marsh","year":"2004","unstructured":"Marsh L. Psychosis in Parkinson\u2019s disease. Curr Treat Options Neurol. 2004;6:181\u20139.","journal-title":"Curr Treat Options Neurol"},{"issue":"4","key":"132_CR19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.parkreldis.2005.10.005","volume":"12","author":"S Papapetropoulos","year":"2006","unstructured":"Papapetropoulos S, McCorquodale DS, Gonzalez J, Jean-Gilles L, Mash DC. Cortical and amygdalar Lewy body burden in Parkinson\u2019s disease patients with visual hallucinations. Parkinsonism Relat Disord. 2006;12(4):253\u20136.","journal-title":"Parkinsonism Relat Disord"},{"issue":"12","key":"132_CR20","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/archneur.1996.00550120077019","volume":"53","author":"JR Sanchez-Ramos","year":"1996","unstructured":"Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson\u2019s disease. Arch Neurol. 1996;53(12):1265\u20138.","journal-title":"Arch Neurol"},{"key":"132_CR21","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/brain\/123.4.733","volume":"123","author":"G Fenelon","year":"2000","unstructured":"Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson\u2019s disease: prevalence, phenomenology and risk factors. Brain. 2000;123:733\u201345.","journal-title":"Brain"},{"issue":"6","key":"132_CR22","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/jnnp.70.6.727","volume":"70","author":"J Barnes","year":"2001","unstructured":"Barnes J, David AS. Visual hallucinations in Parkinson\u2019s disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry. 2001;70(6):727\u201333.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"132_CR23","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/jnnp.70.6.734","volume":"70","author":"S Holroyd","year":"2001","unstructured":"Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2001;70(6):734\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"132_CR24","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00415-005-0918-5","volume":"252","author":"S Papapetropoulos","year":"2005","unstructured":"Papapetropoulos S, Mash DC. Psychotic symptoms in Parkinson\u2019s disease. From description to etiology. J Neurol. 2005;252(7):753\u201364. (REV).","journal-title":"J Neurol"},{"issue":"2","key":"132_CR25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.JGP.0000192480.89813.80","volume":"14","author":"UP Mosimann","year":"2006","unstructured":"Mosimann UP, Rowan EN, Partington CE, et al. Characteristics of visual hallucinations in Parkinson\u2019s disease dementia and dementia with Lewy bodies. Am J Geriatr Psychiatry. 2006;14(2):153\u201360.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"132_CR26","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/jnnp.64.4.533","volume":"64","author":"R Inzelberg","year":"1998","unstructured":"Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1998;64(4):533\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"132_CR27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.wnf.0000144040.20600.c1","volume":"27","author":"SA Factor","year":"2004","unstructured":"Factor SA, Molho ES. Threatening auditory hallucinations and Cotard syndrome in Parkinson disease. Clin Neuropharmacol. 2004;27:205\u20137.","journal-title":"Clin Neuropharmacol"},{"issue":"12","key":"132_CR28","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00415-002-0908-9","volume":"249","author":"G F\u00e9nelon","year":"2002","unstructured":"F\u00e9nelon G, Thobois S, Bonnet AM, Broussolle E, Tison F. Tactile hallucinations in Parkinson\u2019s disease. J Neurol. 2002;249(12):1699\u2013703.","journal-title":"J Neurol"},{"issue":"4","key":"132_CR29","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.parkreldis.2004.01.003","volume":"10","author":"B Tousi","year":"2004","unstructured":"Tousi B, Frankel M. Olfactory and visual hallucinations in Parkinson\u2019s disease. Parkinsonism Relat Dis. 2004;10(4):253\u20134.","journal-title":"Parkinsonism Relat Dis"},{"issue":"2","key":"132_CR30","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/mds.20701","volume":"21","author":"CG Goetz","year":"2006","unstructured":"Goetz CG, Wuu J, Curgian L, Leurgans S. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson\u2019s disease patients. Mov Disord. 2006;21(2):267\u201370.","journal-title":"Mov Disord"},{"issue":"6","key":"132_CR31","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1136\/jnnp.2007.124677","volume":"79","author":"DR Williams","year":"2008","unstructured":"Williams DR, Warren JD, Lees AJ. Using the presence of visual hallucinations to differentiate Parkinson\u2019s disease from atypical Parkinsonism. J Neurol Neurosurg Psychiatry. 2008 Jun;79(6):652\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"132_CR32","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mds.20263","volume":"20","author":"AD Maindreville de","year":"2005","unstructured":"de Maindreville AD Fenelon G Mahieux F. Hallucinations in Parkinson\u2019s disease: a follow-up study. Mov Disord. 2005;20:212\u20137.","journal-title":"Mov Disord"},{"key":"132_CR33","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/mds.20260","volume":"20","author":"HH Fernandez","year":"2005","unstructured":"Fernandez HH, Trieschmann ME, Okun MS. Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson\u2019s disease. Mov Disord. 2005;20:104\u20135.","journal-title":"Mov Disord"},{"key":"132_CR34","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","volume":"75","author":"P Pollak","year":"2004","unstructured":"Pollak P, et al. Clozapine in drug induced psychosis in Parkinson\u2019s disease: a randomized, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75:689\u201395.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"132_CR35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1353-8020(09)70846-6","volume":"4","author":"JM Rabey","year":"2009","unstructured":"Rabey JM. Hallucinations and psychosis in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2009; Suppl. 4:105\u201310.","journal-title":"Parkinsonism Relat Disord"},{"key":"132_CR36","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mds.10450","volume":"18","author":"NJ Diederich","year":"2003","unstructured":"Diederich NJ, Pieri V, Goetz CG. Coping strategies for visual hallucinations in Parkinson\u2019s disease. Mov Disord. 2003;18:831\u20138.","journal-title":"Mov Disord"},{"issue":"4","key":"132_CR37","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00415-006-0388-4","volume":"254","author":"G Kiziltan","year":"2007","unstructured":"Kiziltan G, \u00d4zekmek\u00e7i S, Ertan S, Ertan T, Ergin\u00f6z E. Relationship between age and subtypes of psychotic symptoms in Parkinson\u2019s disease. J Neurol. 2007;254(4):448\u201352.","journal-title":"J Neurol"},{"issue":"3","key":"132_CR38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/PL00007822","volume":"248","author":"EC Wolters","year":"2001","unstructured":"Wolters EC. Intrinsic and extrinsic psychosis in Parkinson\u2019s disease. J Neurol. 2001;248(Suppl\u00a03): 22\u20137.","journal-title":"J Neurol"},{"key":"132_CR39","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/00019052-200108000-00011","volume":"14","author":"EC Wolters","year":"2001","unstructured":"Wolters EC, Berendse HW. Management of psychosis in Parkinson\u2019s disease. Curr Opin Neurol. 2001;14:499\u2013504.","journal-title":"Curr Opin Neurol"},{"key":"132_CR40","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/archneur.63.5.713","volume":"63","author":"CG Goetz","year":"2006","unstructured":"Goetz CG, Fan W, Leurgans S, Bernard B, Stebbins GT. The malignant course of \u201ebenign hallucinations\u201c in Parkinson\u2019s disease. Arch Neurol. 2006;63:713\u20136.","journal-title":"Arch Neurol"},{"key":"132_CR41","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1212\/WNL.57.11.2078","volume":"57","author":"CG Goetz","year":"2001","unstructured":"Goetz CG, Leurgans S, Pappert EJ, Raman R, Stemer AB. Prospective longitudinal assessment of hallucinations in Parkinson\u2019s disease. Neurology. 2001;57:2078\u201382.","journal-title":"Neurology"},{"issue":"4","key":"132_CR42","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/mds.21875","volume":"23","author":"HH Fernandez","year":"2008","unstructured":"Fernandez HH, Aarsland D, F\u00e9nelon G, et al. Scales to Assess psychosis in Parkinson\u2019s disease: critique and recommendations. Mov Disord. 2008;23(4):484\u2013500.","journal-title":"Mov Disord"},{"key":"132_CR43","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/jnnp.67.4.492","volume":"67","author":"D Aarsland","year":"1999","unstructured":"Aarsland D, et al. Range of neuropsychiatric disturbances in patients with Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1999;67:492\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"132_CR44","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1176\/jnp.2006.18.3.402","volume":"18","author":"S Holroyd","year":"2006","unstructured":"Holroyd S, Wooten GF. Preliminary fMRI evidence of visual system dysfunction in Parkinson\u2019s disease patients with visual hallucinations. J Neuropsychiatry Clin Neurosci. 2006;18(3):402\u20134.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"4","key":"132_CR45","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s004150200032","volume":"249","author":"A Schrag","year":"2002","unstructured":"Schrag A, Ben-Shlomo Y, Quinn N. How common are complications of Parkinson\u2019s disease. J Neurol. 2002;249(4):419\u201323.","journal-title":"J Neurol"},{"issue":"7","key":"132_CR46","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archneurol.2011.139","volume":"68","author":"D Weintraub","year":"2011","unstructured":"Weintraub D, Chen P, Ignacio RV, Mamikonyan E, Kales HC. Patterns and trends in antipsychotic prescribing for Parkinson\u2019s disease psychosis. Arch Neurol. 2011;68(7):899\u2013904.","journal-title":"Arch Neurol"},{"issue":"4","key":"132_CR47","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/jnnp.63.4.434","volume":"63","author":"JM Graham","year":"1997","unstructured":"Graham JM, Gr\u00fcnewald RA, Sagar HJ. Hallucinosis in idiopathic Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1997;63(4):434\u201340.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"132_CR48","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/mds.20582","volume":"20","author":"C Pacchetti","year":"2005","unstructured":"Pacchetti C, Manni R, Zangaglia R, et al. Relationship between hallucinations, delusions and REM behavior disorder in Parkinson\u2019s disease. Mov Disord. 2005;20(11):1439\u201348.","journal-title":"Mov Disord"},{"key":"132_CR49","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1001\/jama.1971.03190260031009","volume":"218","author":"FK Goodwin","year":"1971","unstructured":"Goodwin FK. Psychiatric side effects of levodopa in man. JAMA. 1971;218:1915\u201320.","journal-title":"JAMA"},{"key":"132_CR50","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1600-0404.1991.tb04918.x","volume":"84","author":"A Friedman","year":"1991","unstructured":"Friedman A, Sienkiewicz J. Psychotic complications of long-term levodopa treatment of Parkinson\u2019s disease. Acta Neurol Scand. 1991;84:111\u20133.","journal-title":"Acta Neurol Scand"},{"key":"132_CR51","first-page":"115","volume":"65","author":"SA Factor","year":"1995","unstructured":"Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson\u2019s disease: drug-induced psychiatric states. Adv Neurol. 1995;65:115\u201338.","journal-title":"Adv Neurol"},{"key":"132_CR52","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484\u201391.","journal-title":"N Engl J Med"},{"key":"132_CR53","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","volume":"284","author":"Parkinson Study Group.","year":"2000","unstructured":"Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson\u2019s disease: a randomized controlled trial. JAMA. 2000;284:1931\u20138.","journal-title":"JAMA"},{"key":"132_CR54","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00002826-200601000-00014","volume":"29","author":"S Papapetropoulos","year":"2006","unstructured":"Papapetropoulos S. Drug-induced psychosis in Parkinson\u2019s disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol. 2006;29:59.","journal-title":"Clin Neuropharmacol"},{"key":"132_CR55","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/archneur.63.9.1343","volume":"63","author":"SH Fox","year":"2006","unstructured":"Fox SH, Visanji NP, Johnston TH, Gomez-Ramirez J, Voon V, Brotchie JM. Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson\u2019s disease. Arch Neurol. 2006;63:1343\u20134.","journal-title":"Arch Neurol"},{"key":"132_CR56","first-page":"259","volume":"40","author":"P Rondot","year":"1984","unstructured":"Rondot P, de Recondo J, Coignet A, Ziegler M. Mental disorders in Parkinson\u2019s disease after treatment with L-DOPA. Adv Neurol. 1984;40:259\u201369.","journal-title":"Adv Neurol"},{"key":"132_CR57","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1212\/01.wnl.0000191325.31068.c4","volume":"66","author":"G Fenelon","year":"2006","unstructured":"Fenelon G, Goetz CG, Karenberg A. Hallucinations in Parkinson\u2019s disease in the prelevodopa era. Neurology. 2006;66:93\u20138.","journal-title":"Neurology"},{"issue":"5","key":"132_CR58","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1532-5415.1975.tb00187.x","volume":"23","author":"JU Postma","year":"1975","unstructured":"Postma JU, Van Tilburg W. Visual hallucinations and delirium during treatment with amantadine (Symmetrel). J Am Geriatr Soc. 1975;23(5):212\u20135.","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"132_CR59","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s004150050104","volume":"244","author":"C Klein","year":"2007","unstructured":"Klein C, Kompf D, Pulkowski U, Moser A, Vieregge P. A study of visual hallucinations in patients with Parkinson\u2019s disease. J Neurol. 2007;244(6):371\u20137.","journal-title":"J Neurol"},{"key":"132_CR60","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1176\/ajp.135.6.669","volume":"135","author":"C Moskovitz","year":"1978","unstructured":"Moskovitz C, Moses H, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry. 1978;135:669\u201375.","journal-title":"Am J Psychiatry"},{"key":"132_CR61","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1212\/WNL.52.1.10","volume":"52","author":"EC Wolters","year":"1999","unstructured":"Wolters EC. Dopaminomimetic psychosis in Parkinson\u2019s disease patients: diagnosis and treatment. Neurology. 1999;52:10\u20133.","journal-title":"Neurology"},{"issue":"2","key":"132_CR62","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF01663632","volume":"37","author":"W Birkmayer","year":"1975","unstructured":"Birkmayer W, Riederer P. Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post-mortem findings). J Neural Transm. 1975;37(2):175\u201382.","journal-title":"J Neural Transm"},{"key":"132_CR63","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","volume":"340","author":"Parkinson Study Group","year":"1999","unstructured":"Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. N Engl J Med. 1999;340:757\u201363.","journal-title":"N Engl J Med"},{"key":"132_CR64","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/archneurol.2010.35","volume":"67","author":"B Ballanger","year":"2010","unstructured":"Ballanger B, Strafella AP, van Eimeren T, et al. Serotonin 2A receptors and visual hallucinations in Parkinson\u2019s disease. Arch Neurol. 2010;67:416\u201321.","journal-title":"Arch Neurol"},{"issue":"4","key":"132_CR65","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1471-4159.1990.tb03162.x","volume":"55","author":"EK Perry","year":"1990","unstructured":"Perry EK, et al. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem. 1990;55(4):1454\u20136.","journal-title":"J Neurochem"},{"key":"132_CR66","first-page":"393","volume":"45","author":"PJ Whitehouse","year":"1987","unstructured":"Whitehouse PJ. Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson\u2019s disease and Alzheimer\u2019s disease. Adv Neurol. 1987;45:393\u20137.","journal-title":"Adv Neurol"},{"issue":"3","key":"132_CR67","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1006\/brcg.1995.1255","volume":"28","author":"EK Perry","year":"1995","unstructured":"Perry EK, Perry RH. Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn. 1995;28(3):240\u201358.","journal-title":"Brain Cogn"},{"issue":"17","key":"132_CR68","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/mds.21683","volume":"22","author":"PT Francis","year":"2007","unstructured":"Francis PT, Perry EK. Cholinergic and other neurotransmitter mechanisms in Parkinson\u2019s disease, Parkinson\u2019s disease dementia, and dementia with Lewy bodies. Mov Disord. 2007;22(Suppl\u00a017):351\u20137.","journal-title":"Mov Disord"},{"issue":"3","key":"132_CR69","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ana.410400309","volume":"40","author":"DE Kuhl","year":"1996","unstructured":"Kuhl DE, Minoshima S, Fessler JA, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer\u2019s disease, and Parkinson\u2019s disease. Ann Neurol. 1996;40(3):399\u2013410.","journal-title":"Ann Neurol"},{"key":"132_CR70","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0166-2236(98)01361-7","volume":"22","author":"EK Perry","year":"1999","unstructured":"Perry EK, Walker M, Grace J, Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. 1999;22:273\u201380.","journal-title":"Trends Neurosci"},{"issue":"2","key":"132_CR71","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/brain\/awf033","volume":"125","author":"AJ Harding","year":"2002","unstructured":"Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002;125(Pt 2):391\u2013403.","journal-title":"Brain"},{"issue":"10","key":"132_CR72","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(05)70146-0","volume":"4","author":"DR Williams","year":"2005","unstructured":"Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson\u2019s disease: a retrospective autopsy study. Lancet Neurol. 2005;4(10):605\u201310.","journal-title":"Lancet Neurol"},{"issue":"12","key":"132_CR73","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/mds.21140","volume":"21","author":"H Matsui","year":"2006","unstructured":"Matsui H, Nishinaka K, Oda M, et al. Hypoperfusion of the visual pathway in parkinsonian patients with visual hallucinations. Mov Disord. 2006;21(12):2140\u20134.","journal-title":"Mov Disord"},{"issue":"5","key":"132_CR74","first-page":"289","volume":"21","author":"NJ Diederich","year":"1998","unstructured":"Diederich NJ, Goetz CG, Raman R, Pappert EJ, Leurgans S, Piery V. Poor visual discrimination and visual hallucinations in Parkinson\u2019s disease. Clin Neuropharmacol. 1998;21(5):289\u201395.","journal-title":"Clin Neuropharmacol"},{"issue":"8","key":"132_CR75","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/archneur.59.8.1249","volume":"59","author":"NJ Diederich","year":"2002","unstructured":"Diederich NJ, Raman R, Leurgans S, Goetz CG. Progressive worsening of spatial and chromatic processing deficits in Parkinson\u2019s disease. Arch Neurol. 2002;59(8):1249\u201352.","journal-title":"Arch Neurol"},{"issue":"2","key":"132_CR76","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1353-8020(03)00022-1","volume":"9","author":"I Bodis-Wollner","year":"2003","unstructured":"Bodis-Wollner I. Neuropsychological and perceptual defects in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2003;9(Suppl\u00a02):83\u20139.","journal-title":"Parkinsonism Relat Disord"},{"key":"132_CR77","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1212\/01.WNL.0000145764.70698.4E","volume":"63","author":"UP Mosimann","year":"2004","unstructured":"Mosimann UP, et al. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology 2004;63:2091\u20136.","journal-title":"Neurology"},{"issue":"8","key":"132_CR78","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1212\/01.WNL.0000141853.27081.BD","volume":"63","author":"GT Stebbins","year":"2004","unstructured":"Stebbins GT, Goetz CG, Carrillo MC, et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology. 2004;63(8):1409\u201316.","journal-title":"Neurology"},{"issue":"10","key":"132_CR79","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1212\/01.WNL.0000161872.85903.8E","volume":"64","author":"D Paleacu","year":"2005","unstructured":"Paleacu D, Schechtman E, Inzelberg R. Association between family history of dementia and hallucinations in Parkinson disease. Neurology. 2005;64(10):1712\u20135.","journal-title":"Neurology"},{"issue":"1","key":"132_CR80","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00008571-200002000-00006","volume":"10","author":"AJ Makoff","year":"2000","unstructured":"Makoff AJ, Graham JM, Arranz MJ, et al. Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson\u2019s disease. Pharmacogenetics. 2000;10(1):43\u20138.","journal-title":"Pharmacogenetics"},{"issue":"2","key":"132_CR81","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archneur.58.2.209","volume":"58","author":"CG Goetz","year":"2001","unstructured":"Goetz CG, Burke PF, Leurgans S, et al. Genetic variation analysis in Parkinson\u2019s disease patients with and without hallucinations: case-control study. Arch Neurol. 2001;58(2):209\u201313.","journal-title":"Arch Neurol"},{"issue":"3","key":"132_CR82","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.neulet.2003.11.006","volume":"355","author":"J Wang","year":"2004","unstructured":"Wang J, Zhao C, Chen B, Liu ZL. Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson\u2019s disease. Neurosci Lett. 2004;355(3):193\u20136.","journal-title":"Neurosci Lett"},{"issue":"3","key":"132_CR83","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.neulet.2007.06.028","volume":"422","author":"L Kiferle","year":"2007","unstructured":"Kiferle L, Ceravolo R, Petrozzi L, et al. Visual hallucinations in Parkinson\u2019s disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes. Neurosci Lett. 2007;422(3):228\u201331.","journal-title":"Neurosci Lett"},{"issue":"4","key":"132_CR84","first-page":"226","volume":"22","author":"R De la Fuente-Fernandez","year":"1999","unstructured":"De la Fuente-Fernandez R Nunez MA Lopez E. The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson\u2019s disease. Clin Neuropharmacol. 1999;22(4):226\u201330.","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"132_CR85","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0404.2005.00535.x","volume":"113","author":"B Feldman","year":"2006","unstructured":"Feldman B, Chapman J, Korczyn AD. Apolipoprotein epsilon4 advances appearance of psyhosis in patients with Parkinson\u2019s disease. Acta Neurol Scand 2006;113(1):14\u20137.","journal-title":"Acta Neurol Scand"},{"issue":"8","key":"132_CR86","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/mds.20481","volume":"20","author":"R Camicioli","year":"2005","unstructured":"Camicioli R, Rajput A, Rajput M, Reece C, Payami H, Hao C, Rajput A. Apolipoprotein E epsilon4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson\u2019s disease: relationship to dementia and hallucinations. Mov Disord. 2005;20(8):989\u201394.","journal-title":"Mov Disord"},{"issue":"12","key":"132_CR87","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/mds.23806","volume":"26","author":"SA Factor","year":"2011","unstructured":"Factor SA, Steenland NK, Higgins DS, Molho ES, Kay DM, Montimurro J, Rosen AR, Zabetian CP, Payami H. Disease-related and genetic correlates of psychotic symptoms in Parkinson\u2019s disease. Mov Disord. 2011;26(12):2190\u20135.","journal-title":"Mov Disord"},{"issue":"5","key":"132_CR88","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/gps.389","volume":"16","author":"D Aarsland","year":"2001","unstructured":"Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson\u2019s disease with and without dementia. Int J Geriatr Psychiatry. 2001;16(5):528\u201336.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"132_CR89","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s007020050005","volume":"107","author":"N Giladi","year":"2000","unstructured":"Giladi N, Treves A, Paleacu D, et al. Risk factors for dementia, depression, and psychosis in long-standing Parkinson\u2019s disease. J Neural Transm. 2000;107(1):59\u201371.","journal-title":"J Neural Transm"},{"issue":"2","key":"132_CR90","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1212\/01.wnl.0000265593.34438.00","volume":"69","author":"KM Biglan","year":"2007","unstructured":"Biglan KM, Holloway RG, McDermott MP, Richard IH, Parkinson Study Group CALM-PD Investigators. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology. 2007;69(2):187\u201395.","journal-title":"Neurology"},{"issue":"1","key":"132_CR91","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1471-2377-13-145","volume":"13","author":"H Sawada","year":"2013","unstructured":"Sawada H, Oeda T, Yamamoto K, Umemura A, Tomita S, Hayashi R, Kohsaka M, Kawamura T. Trigger medications and patient-related risk factors for Parkinson\u2019s disease psychosis requiring anti-psychotic drugs: a retrospective cohort study. BMC Neurol. 2013;13(1):145.","journal-title":"BMC Neurol"},{"issue":"1","key":"132_CR92","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/1531-8257(199901)14:1<117::AID-MDS1019>3.0.CO;2-0","volume":"14","author":"EJ Pappert","year":"1999","unstructured":"Pappert EJ, Goetz CG, Niederman FG, et al. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson\u2019s disease. Mov Disord. 1999;14(1):117\u201321.","journal-title":"Mov Disord"},{"issue":"1","key":"132_CR93","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1212\/01.WNL.0000148479.10865.FE","volume":"64","author":"CG Goetz","year":"2005","unstructured":"Goetz CG, Wuu J, Curgian LM, Leurgans S. Hallucinations and sleep disorders in PD. Six-year prospective longitudinal study. Neurology. 2005;64(1):81\u20136.","journal-title":"Neurology"},{"issue":"5","key":"132_CR94","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ana.410340514","volume":"34","author":"CL Comella","year":"1993","unstructured":"Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson\u2019s disease patients with treatment-induced hallucinations. Ann Neurol. 1993;34(5):710\u20134.","journal-title":"Ann Neurol"},{"issue":"2","key":"132_CR95","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1212\/WNL.55.2.281","volume":"55","author":"I Arnulf","year":"2000","unstructured":"Arnulf I, Bonnet A-M, Damier P, et al. Hallucinations, REM sleep, and Parkinson\u2019s disease: a medical hypothesis. Neurology. 2000;55(2):281\u20138.","journal-title":"Neurology"},{"issue":"6","key":"132_CR96","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00023210-199911060-00005","volume":"11","author":"HH Fernandez","year":"1999","unstructured":"Fernandez HH, Friedman JF. The role of atypical antipsychotics in the treatment of movement disorders. CNS Drugs. 1999;11(6):467\u201383. 92.","journal-title":"CNS Drugs"},{"key":"132_CR97","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00127893-200006010-00004","volume":"6","author":"JH Friedman","year":"2000","unstructured":"Friedman JH, Fernandez HH. The non-motor problems of Parkinson\u2019s disease. Neurology. 2000;6:18\u201327.","journal-title":"Neurology"},{"key":"132_CR98","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/09540260020002541","volume":"12","author":"MJ Henderson","year":"2000","unstructured":"Henderson MJ, Mellers JDC. Psychosis in Parkinson\u2019s disease: \u201ebetween a rock and a hard place\u201c. Int Rev Psychiatry. 2000;12:319\u201334.","journal-title":"Int Rev Psychiatry"},{"issue":"3","key":"132_CR99","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.euroneuro.2006.08.007","volume":"17","author":"H Frieling","year":"2007","unstructured":"Frieling H, Hillemacher T, Ziegenbein M, Neundorfer B, Bleich S. Treating dopamimetic psychosis in Parkinson\u2019s disease: structured review and meta-analysis. Eur Neuropsychopharmacol. 2007;17(3):165\u201371.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"132_CR100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/mds.23884","volume":"26","author":"K Seppi","year":"2011","unstructured":"Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson\u2019s disease. Mov Disord. 2011;26(Suppl\u00a03):42\u201380.","journal-title":"Mov Disord"},{"issue":"3","key":"132_CR101","first-page":"3","volume":"59","author":"G Honigfeld","year":"1998","unstructured":"Honigfeld G, Arellano F, Sethi J, et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry. 1998;59(Suppl 3):3\u20137.","journal-title":"J Clin Psychiatry"},{"key":"132_CR102","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/1531-8257(200011)15:6<1230::AID-MDS1026>3.0.CO;2-9","volume":"15","author":"E Mohr","year":"2000","unstructured":"Mohr E, Mendis T, Hildebrand K, et al. Risperidone in the treatment of dopamine-induced psychosis in Parkinson\u2019s disease: an open pilot trial. Mov Disord. 2000;15:1230\u20137.","journal-title":"Mov Disord"},{"key":"132_CR103","unstructured":"Parsa MA, Lebedeva, Z, Riley D, Poggi E, Lebedeva T. Low-dose risperidone in the treatment of levodopa-induced psychosis and dyskinesia in patients with Parkinson\u2019s disease. Poster, Annual Meeting of International College of Geriatric Psychoneuropharmachology, San Juan, Puerto Rico, December 12\u201314, 2003."},{"key":"132_CR104","doi-asserted-by":"crossref","unstructured":"Workman RH Jr., Orengo CA, Bakey AA, Molinari VA, Kunik ME. The use of risperidone for psychosis and agitation in demented patients with Parkinson\u2019s disease. J Neuropsychiatry Clin Neurosci. 1997;9(4):594\u20137.","DOI":"10.1176\/jnp.9.4.594"},{"key":"132_CR105","first-page":"556","volume":"56","author":"SS Rich","year":"1995","unstructured":"Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson\u2019s disease and other akinetic-rigid syndromes. J Clin Psychiatry. 1995;56:556\u20139.","journal-title":"J Clin Psychiatry"},{"key":"132_CR106","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1176\/jnp.12.3.364","volume":"12","author":"T Ellis","year":"2000","unstructured":"Ellis T, Cudkowicz ME, Sexton PM, et al. Clozapine and risperidone treatment of psychosis in Parkinson\u2019s disease. J Neuropsychiatry Clin Neurosci. 2000;12:364\u201369.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"132_CR107","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/mds.870120423","volume":"12","author":"G Meco","year":"1997","unstructured":"Meco G, Alessandri A, Giustini P, et al. Risperidone in levodopa-induced psychosis in advanced Parkinson\u2019s disease: an open-label, long-term study. Mov Disord. 1997;12:610\u20132.","journal-title":"Mov Disord"},{"issue":"4","key":"132_CR108","first-page":"211","volume":"60","author":"A Rustembegovic","year":"2006","unstructured":"Rustembegovic A, Sofic E, Wichart I. Serum prolactin, leptin, lipids and lipoproteins levels during antipsychotics treatment in Parkinson's disease and related psychosis. Med Arh. 2006;60(4):211\u20132.","journal-title":"Med Arh"},{"key":"132_CR109","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/1531-8257(199911)14:6<1014::AID-MDS1017>3.0.CO;2-9","volume":"14","author":"ES Molho","year":"1999","unstructured":"Molho ES, Factor SA. Worsening of motor features of Parkinsonism with olanzapine. Mov Disord. 1999;14:1014\u20136.","journal-title":"Mov Disord"},{"key":"132_CR110","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0006-3223(02)01392-6","volume":"52","author":"A Breier","year":"2002","unstructured":"Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson\u2019s disease. Biol Psychiatry. 2002;52:438\u201345.","journal-title":"Biol Psychiatry"},{"key":"132_CR111","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/mds.10217","volume":"17","author":"WG Ondo","year":"2002","unstructured":"Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002;17:1031\u20135.","journal-title":"Mov Disord"},{"key":"132_CR112","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1212\/WNL.55.6.789","volume":"55","author":"CG Goetz","year":"2000","unstructured":"Goetz CG, Blasucci LM, Leurgans S, et al. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology. 2000;55:789\u201394.","journal-title":"Neurology"},{"key":"132_CR113","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/mds.10176","volume":"17","author":"S Reddy","year":"2002","unstructured":"Reddy S, Factor SA, Molho ES, et al. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord. 2002;17:676\u201381.","journal-title":"Mov Disord"},{"key":"132_CR114","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.10374","volume":"18","author":"HH Fernandez","year":"2003","unstructured":"Fernandez HH, Trieschmann ME, Burke MA, et al. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord. 2003;18:510\u20134.","journal-title":"Mov Disord"},{"issue":"8","key":"132_CR115","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/mds.20474","volume":"20","author":"WG Ondo","year":"2005","unstructured":"Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson\u2019s disease. Mov Disord. 2005;20(8):958\u201363.","journal-title":"Mov Disord"},{"issue":"3","key":"132_CR116","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.21116","volume":"22","author":"JM Rabey","year":"2007","unstructured":"Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson\u2019s disease patients: a double-blind labeled study of 3 months\u2019 duration. Mov Disord. 2007;22(3):313\u20138.","journal-title":"Mov Disord"},{"issue":"17","key":"132_CR117","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1212\/01.wnl.0000260060.60870.89","volume":"68","author":"R Kurlan","year":"2007","unstructured":"Kurlan R, Cummings J, Raman R, Thal L, Alzheimer\u2019s Disease Cooperative Study Group. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68(17):1356\u201363.","journal-title":"Neurology"},{"key":"132_CR118","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.wnf.0000136891.17006.ec","volume":"27","author":"L Morgante","year":"2004","unstructured":"Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004;27:153\u20136.","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"132_CR119","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.WNF.0000236769.31279.19","volume":"29","author":"D Merims","year":"2006","unstructured":"Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson\u2019s disease psychosis. Clin Neuropharmacol. 2006;29(6):331\u20137.","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"132_CR120","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/01.WNF.0000228176.98582.93","volume":"29","author":"C Klein","year":"2006","unstructured":"Klein C, Prokhorov T, Miniovich A, Dobronevsky E, Rabey JM. Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis. Clin Neuropharmacol. 2006;29(4):215\u20139.","journal-title":"Clin Neuropharmacol"},{"issue":"7","key":"132_CR121","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1111\/j.1445-5994.2011.02499.x","volume":"42","author":"K Bloomfield","year":"2012","unstructured":"Bloomfield K, MacDonald L, Finucane G, Snow B, Roxburgh R. Use of antipsychotic medications in patients with Parkinson\u2019s disease at Auckland City Hospital. Intern Med J. 2012;42(7):e151\u20136.","journal-title":"Intern Med J"},{"issue":"3","key":"132_CR122","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/01.wnf.0000164297.91643.ff","volume":"28","author":"JC G\u00f3mez-Esteban","year":"2005","unstructured":"G\u00f3mez-Esteban JC, Zarranz JJ, Velasco F, Lezcano E, Lachen MC, Rouco I, Barcena J, Boyero S, Ciordia R, Allue I. Use of ziprasidone in parkinsonian patients with psychosis. Clin Neuropharmacol. 2005;28(3):111\u20134.","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"132_CR123","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.clineuro.2006.07.003","volume":"109","author":"J Schindeh\u00fctte","year":"2007","unstructured":"Schindeh\u00fctte J, Trenkwalder C. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Clin Neurol Neurosurg. 2007;109(2):188\u201391.","journal-title":"Clin Neurol Neurosurg"},{"issue":"2","key":"132_CR124","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/WNF.0b013e31824d5115","volume":"35","author":"L Pintor","year":"2012","unstructured":"Pintor L, Valldeoriola F, Baill\u00e9s E, Mart\u00ed MJ, Mu\u00f1iz A, Tolosa E. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. Clin Neuropharmacol. 2012;35(2):61\u20136.","journal-title":"Clin Neuropharmacol"},{"key":"132_CR125","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00002826-200401000-00003","volume":"27","author":"HH Fernandez","year":"2004","unstructured":"Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol. 2004;27:4\u20135.","journal-title":"Clin Neuropharmacol"},{"key":"132_CR126","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1176\/appi.ajp.161.2.373-a","volume":"161","author":"C Schonfeldt-Lecuona","year":"2004","unstructured":"Schonfeldt-Lecuona C, Connemann BJ. Aripiprazole and Parkinson\u2019s disease psychosis. Am J Psychiatry. 2004;161:373\u20134.","journal-title":"Am J Psychiatry"},{"key":"132_CR127","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/mds.21091","volume":"21","author":"JH Friedman","year":"2006","unstructured":"Friedman JH, Berman RM, Goetz CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson\u2019s disease. Mov Disord. 2006;21:2078\u201381.","journal-title":"Mov Disord"},{"key":"132_CR128","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00002826-199208000-00008","volume":"15","author":"B Ott","year":"1992","unstructured":"Ott B, Lannon M. Exacerbation of parkinsonism by tacrine. Clin Neuropharmacol. 1992;15:322\u20135.","journal-title":"Clin Neuropharmacol"},{"key":"132_CR129","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/jnnp.61.3.324-a","volume":"61","author":"M Hutchinson","year":"1996","unstructured":"Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1996;61:324\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"132_CR130","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00002826-200203000-00009","volume":"25","author":"J Bergman","year":"2002","unstructured":"Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson\u2019s disease. Clin Neuropharmacol. 2002;25:107\u201310.","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"132_CR131","first-page":"276","volume":"41","author":"T. Sobow","year":"2007","unstructured":"Sobow T. Parkinson\u2019s disease-related visual hallucinations unresponsive to atypical antipsychotics treated with cholinesterase inhibitors: a case series. Neurol Neurochir Pol. 2007;41(3):276\u20139.","journal-title":"Neurol Neurochir Pol"},{"key":"132_CR132","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s100720200022","volume":"23","author":"G Fabbrini","year":"2002","unstructured":"Fabbrini G, Barbanti P, Aurilia C, et al. Donepezil in the treatment of hallucinations and delusions in Parkinson\u2019s disease. Neurol Sci. 2002;23:41\u20133.","journal-title":"Neurol Sci"},{"key":"132_CR133","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/0891988703256054","volume":"16","author":"A Kurita","year":"2003","unstructured":"Kurita A, Ochiai Y, Kono Y, et al. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson\u2019s disease. J Geriatr Psychiatry Neurol. 2003;16:184\u20138.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"132_CR134","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/gps.949","volume":"18","author":"D Aarsland","year":"2003","unstructured":"Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson\u2019s disease with dementia. Int J Geriatr Psychiatry. 2003;18:937\u201341.","journal-title":"Int J Geriatr Psychiatry"},{"key":"132_CR135","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1185\/030079902125000813","volume":"18","author":"R Bullock","year":"2002","unstructured":"Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson\u2019s disease: a case series. Curr Med Res Opin. 2002;18:258\u201364.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"132_CR136","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","volume":"35","author":"HY Meltzer","year":"2010","unstructured":"Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, Friedman JH. Primavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson\u2019s disease psychosis. Neuropsychopharmacology. 2010;35(4):881\u201392.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"132_CR137","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1017\/S0317167100027141","volume":"15","author":"TA Hurwitz","year":"1988","unstructured":"Hurwitz TA, Calne DB, Waterman K. Treatment of dopamimetic psychosis in Parkinson\u2019s disease with electroconvulsive therapy. Can J Neurol Sci. 1988;15(1):32\u20134.","journal-title":"Can J Neurol Sci"},{"issue":"3","key":"132_CR138","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1176\/jnp.7.3.304","volume":"7","author":"SA Factor","year":"1995","unstructured":"Factor SA, Molho ES, Brown DL. Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson\u2019s disease. J Neuropsychiatry Clin Neurosci. 1995;7(3):304\u20137.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"2","key":"132_CR139","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/01.yct.0000159325.08303.45","volume":"21","author":"F Ozer","year":"2005","unstructured":"Ozer F, Meral H, Aydin B, et al. Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome. J ECT. 2005;21(2):125\u20137.","journal-title":"J ECT"},{"issue":"2","key":"132_CR140","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4103\/0019-5545.82549","volume":"53","author":"K Muralidharan","year":"2011","unstructured":"Muralidharan K, Thimmaiah R, Chakraborty V, Jain S. Bifrontal ECT for drug-induced psychosis in Parkinson\u2019s disease. Indian J Psychiatry. 2011;53(2):156\u20138.","journal-title":"Indian J Psychiatry"},{"issue":"2","key":"132_CR141","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/YCT.0b013e3181c18a3d","volume":"26","author":"S Ueda","year":"2010","unstructured":"Ueda S, Koyama K, Okubo Y. Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease. J ECT. 2010;26(2):111\u20135.","journal-title":"J ECT"},{"issue":"7","key":"132_CR142","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.pnpbp.2011.05.003","volume":"35","author":"C Usui","year":"2011","unstructured":"Usui C, Hatta K, Doi N, Kubo S, Kamigaichi R, Nakanishi A, Nakamura H, Hattori N, Arai H. Improvements in both psychosis and motor signs in Parkinson\u2019s disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(7):1704\u20138.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"132_CR143","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1479-8301.2012.00432.x","volume":"13","author":"K Tagai","year":"2013","unstructured":"Tagai K, Nagata T, Shinagawa S, Tsuno N, Ozone M, Nakayama K. Mirtazapine improves visual hallucinations in Parkinson's disease: a case report. Psychogeriatrics. 2013;13(2):103\u20137.","journal-title":"Psychogeriatrics"},{"key":"132_CR144","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1055\/s-2007-979504","volume":"30","author":"C Normann","year":"1997","unstructured":"Normann C, Hesslinger B, Frauenknecht S, et al. Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine. Pharmacopsychiatry. 1997;30:263\u20135.","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"132_CR145","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF02190411","volume":"244","author":"K Ikeguchi","year":"1995","unstructured":"Ikeguchi K, Kuroda A. Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Eur Arch Psychiatry Clin Neurosci. 1995;244(6):320\u20134.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"132_CR146","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/00002826-200403000-00009","volume":"27","author":"V Voon","year":"2004","unstructured":"Voon V, Lang AE. Antidepressants in the treatment of psychosis with comorbid depression in Parkinson\u2019s disease. Clin Neuropharmacol. 2004;27:90\u20132.","journal-title":"Clin Neuropharmacol"},{"key":"132_CR147","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pnpbp.2006.06.016","volume":"31","author":"G Meco","year":"2007","unstructured":"Meco G, Bernardi S. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson\u2019s disease. Prof Neuropsychopharmacol Biol Psychiatry. 2007;31:311\u20133.","journal-title":"Prof Neuropsychopharmacol Biol Psychiatry"},{"key":"132_CR148","first-page":"1750","volume":"150","author":"EC Lauterbach","year":"1993","unstructured":"Lauterbach EC. Dopaminergic hallucinosis with fluoxetine in Parkinson\u2019s disease. Am J Psychiatry. 1993;150:1750.","journal-title":"Am J Psychiatry"},{"issue":"9916","key":"132_CR149","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J. Cummings","year":"2014","unstructured":"Cummings, J., Isaacson, S., Mills. R., Williams, H., Chi-Burris, K., Corbett, A., Dhall, R., Ballard, C. Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533\u201340.","journal-title":"Lancet"},{"key":"132_CR150","unstructured":"Poewe W. Nonmotor symptoms in Parkinson\u2019s disease. In: Jankovic J, Tolosa E, Herausgebers. Parkinson\u2019s disease & movement disorders. Philadelphia, Lippincott Williams & Wilkins; 2007."},{"issue":"15","key":"132_CR151","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/mds.22589","volume":"24","author":"D Aarsland","year":"2009","unstructured":"Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson\u2019s disease. Mov Disord. 2009;24(15):2175\u201386.","journal-title":"Mov Disord"},{"issue":"39","key":"132_CR152","first-page":"684","volume":"107","author":"B Mollenhauer","year":"2010","unstructured":"Mollenhauer B, F\u00f6rstl H, Deuschl G, Storch A, Oertel W, Trenkwalder C. Lewy body and Parkinsonian dementia: common, but often misdiagnosed conditions. Dtsch Arztebl Int 2010;107(39):684\u201391.","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"132_CR153","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/jnnp.2008.152579","volume":"8","author":"W Poewe","year":"2008","unstructured":"Poewe W. When a Parkinson\u2019s disease patient starts to hallucinate. Pract Neurol. 2008;8(4):238\u201341.","journal-title":"Pract Neurol"},{"key":"132_CR154","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1532-5415.1991.tb03627.x","volume":"39","author":"JL Cummings","year":"1991","unstructured":"Cummings JL. Behavioral complications of drug treatment of Parkinson\u2019s disease. J Am Geriatr Soc. 1991;39:708\u201316.","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"132_CR155","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/1531-8257(200003)15:2<301::AID-MDS1014>3.0.CO;2-2","volume":"15","author":"NA Leopold","year":"2000","unstructured":"Leopold NA. Risperidone treatment of drug-related psychosis in patients with parkinsonism. Mov Disord. 2000;15(2):301\u20134.","journal-title":"Mov Disord"},{"issue":"4","key":"132_CR156","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1212\/WNL.47.4.1085","volume":"47","author":"EC Wolters","year":"1996","unstructured":"Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmans PL. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson\u2019s disease. Neurology. 1996;47(4):1085\u20137.","journal-title":"Neurology"},{"issue":"7","key":"132_CR157","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1136\/jnnp.2004.050682","volume":"76","author":"B Ravina","year":"2005","unstructured":"Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson\u2019s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005;76(7):934\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"132_CR158","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/mds.1204","volume":"16","author":"PJ Reading","year":"2001","unstructured":"Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord. 2001;16(6):1171\u20134.","journal-title":"Mov Disord"},{"issue":"11","key":"132_CR159","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/mds.21077","volume":"21","author":"D Burn","year":"2006","unstructured":"Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson\u2019s disease. Mov Disord. 2006;21(11):1899\u2013907.","journal-title":"Mov Disord"}],"container-title":["neuropsychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40211-014-0132-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40211-014-0132-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40211-014-0132-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:23:28Z","timestamp":1559503408000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40211-014-0132-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,14]]},"references-count":159,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["132"],"URL":"https:\/\/doi.org\/10.1007\/s40211-014-0132-8","relation":{},"ISSN":["0948-6259","2194-1327"],"issn-type":[{"value":"0948-6259","type":"print"},{"value":"2194-1327","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,14]]}}}